Clinical Review Gene-based therapies for ALIARDS where are we now.docVIP

Devaney et al. Critical Care 2011,15:224 /content/15/3/224 RE VIE W Clinical Review: Gene-based therapies for ALI/ARDS: where are we now? James Devaney , Maya Contreras and John G La? ey * 1 1,2 1,2,3 ALI/ARDS with a 40% mortality rate, amounting to 75,000 deaths annually [2]. Signi? cant ongoing morbidity, including pulmonary, neuromuscular, cognitive and psychiatric sequelae, is seen in 50 to 70% of ALI/ARDS survivors, and the ? nancial burden on s